English
Stock of the day
Telix Pharmaceuticals
Telix Pharmaceuticals sees a rise in shares following the US approval for reimbursement of its prostate cancer imaging agent.
(AI video summary)
This video was created on 23 September 2025 for IG audiences by ausbiz.
ASX code: TLX
Reimbursement approval sparks optimism
Telix Pharmaceuticals announced that the United States (US) Centers for Medicare and Medicaid Services approved reimbursement for their prostate cancer imaging agent. Last Friday, Citi began coverage on Telix with a high-risk 'buy' rating, forecasting that the company's base business will exceed market expectations
Market reaction
Telix shares rose 5.6%, showing increased investor confidence. Analysts noted that the company's shares were set for a positive turn following previous regulatory setbacks on two drugs, where the Food and Drug Administration (FDA) requested more information, rather than rejections. Analysts have upgraded their outlook from 'hold' to 'buy', anticipating further positive announcements.
Investment outlook
The recent government funding approval boosts the company’s financial outlook. Analysts suggest that if positive updates continue, Telix's stock may rise 60 to 80% in line with analysts' price targets. However, they suggest focusing on the business's prospects over the volatile share price.
Important to know
This information has been prepared by IG, a trading name of IG Australia Pty Ltd. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Ready to open an IG account?
Start your trading journey now
Follow us online:
